1434060-97-5

Basic information

• Product Name: (E)-6-(4-(3,5-dimethoxystyryl)phenoxy)-N-ethyl-N-(2-methoxybenzyl)hexan-1-amine
• Synonyms: (E)-6-(4-(3,5-dimethoxystyryl)phenoxy)-N-ethyl-N-(2-methoxybenzyl)hexan-1-amine
• CAS NO: 1434060-97-5
• Molecular Weight: 503.682
• Mol File: 1434060-97-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (E)-6-(4-(3,5-dimethoxystyryl)phenoxy)-N-ethyl-N-(2-methoxybenzyl)hexan-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-6-(4-(3,5-dimethoxystyryl)phenoxy)-N-ethyl-N-(2-methoxybenzyl)hexan-1-amine(1434060-97-5)
• EPA Substance Registry System: (E)-6-(4-(3,5-dimethoxystyryl)phenoxy)-N-ethyl-N-(2-methoxybenzyl)hexan-1-amine(1434060-97-5)

Safety Data

• Hazardous Substances Data: 1434060-97-5(Hazardous Substances Data)

Upstream product

• 141823-14-5 4-((6-bromohexyl)oxy)benzaldehyde 
• 123-08-0 4-hydroxy-benzaldehyde 
• 877-88-3 3,5-dimethoxybenzyl bromide 
• 108957-75-1 diethyl 3,5-dimethoxybenzylphosphonate 
• 705-76-0 3,5-dimethoxybenzyl alcohol 
• 629-03-8 1 ,6-dibromohexane 

Relevant articles and documents

Multitarget-directed resveratrol derivatives: Anti-cholinesterases, anti-β-amyloid aggregation and monoamine oxidase inhibition properties against Alzheimer's disease

Considering the complex pathogenesis factors of Alzheimer's disease (AD), the multitarget-directed ligand strategy is expected to provide superior effects to fight AD, instead of the classic one-drug-one-target strategy. Resveratrol, exhibiting important properties against AD, was suggested to be used as a starting compound for the treatment of AD. Based on these reasons, a series of resveratrol derivatives were designed, synthesized and biologically evaluated. Among them, compound 6r, exhibiting moderate cholinesterase inhibition activity (AChE, IC50 = 6.55 μM; BuChE, IC50 = 8.04 μM; SI = 1.23), significant inhibition of Aβ42 aggregation (57.78%, at 20 μM) and acceptable inhibitory activity against monoamine oxidases (MAO-A, IC50 = 17.58 μM; MAO-B, IC50 = 12.19 μM), was a potential anti-Alzheimer agent with balanced activities. Consequently, this study provided useful information for further development of resveratrol derivatives as multitarget-directed agents for AD therapy. This journal is the Partner Organisations 2014.